Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4, as well as targeted therapies such as BRAF/MEK inhibitors, have transformed the landscape of advanced or unresectable melanoma wherein 5-year survival rates of 30%-50% have been achieved in phase III clinical trials.4–6. Here, MAP2K7 is linked to melanoma.